With Claimed Designated Perfecting Feature In Contents (e.g., Excipient, Lubricant, Etc.) Patents (Class 424/452)
  • Patent number: 11219228
    Abstract: Provided is a liquid system comprising a first component and a second component the components selected from the group consisting of carbohydrates, sugar alcohols, food grade acids, food grade non-aqueous solvents and food grade salts wherein: a. the second component is different than the first component; b. the system has a melting point lower than each of the components; and c. the liquid system comprises 7% or less water. The systems are useful for protecting an active ingredient in a food system wherein the ingredient is stable at room temperature and retains its sensory properties after being diluted into an aqueous beverage for example to form a flavored aqueous beverage.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 11, 2022
    Assignee: FIRMENICH SA
    Inventors: Ronald H. Skiff, Ernst L. Steinboeck, Jean-Francois Basset
  • Patent number: 11160792
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: November 2, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 11135159
    Abstract: The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 5, 2021
    Inventors: Rudolph Wilhelm, Markus Pröls, Roland Greinwald, Tanju Nacak
  • Patent number: 11110067
    Abstract: Disclosed are microcapsules that include an inhibitor of the mammalian target of rapamycin (mTOR) within the microcapsules, and pharmaceutical compositions and kits that include the microcapsules. Also disclosed are methods for treating or preventing an age-related disease, condition, or disorder in a subject that involve administering to a subject a pharmaceutically effective amount of microcapsules that includes an inhibitor of mTOR within the microcapsules.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: September 7, 2021
    Assignees: The Board of Regents of the University of Texas System, Southwest Research Institute
    Inventors: Zelton Dave Sharp, John R. Strong, Veronica Galvan, Salvatore Oddo, Herbert G. Wheeler
  • Patent number: 11090291
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: August 17, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 11052049
    Abstract: The present disclosure provides for a capsule dosage form of triamterene, the dosage form comprising: a) triamterene having a weight percentage in a range of 25-45% with respect to the total ingredients in the capsule dosage form; b) magnesium stearate having a weight percentage in a range of 1.5-13% with respect to the total ingredients in the capsule dosage form; and c) at least one diluent having a weight percentage in a range of 42-73.5% with respect to the total mixture/ingredients encapsulated in the capsule dosage form. The present disclosure also provides for a convenient process for preparation of the capsule dosage form.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: July 6, 2021
    Assignee: ATOZ PHARMACEUTICALS PVT LTD
    Inventors: Natarajan Venkatachalam, Olaganathan Arumugam
  • Patent number: 11033505
    Abstract: The present invention relates to an oral complex preparation comprising: a capsule containing a fat-soluble first drug; and a solid preparation containing a second drug, the solid preparation being embedded into the capsule and including an oil-proof material coating layer on the surface thereof The oral complex preparation of the present invention prepared by embedding the solid preparation including the oil-proof material coating layer on the surface thereof and containing the second drug into the capsule containing the fat-soluble first drug enables two types of drug ingredients to be simultaneously administered.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: June 15, 2021
    Assignees: Korea United Pharm, Inc., United Science R&D Center
    Inventors: Yun Woong Choi, Dae Chul Ha, In Ho Kwon, Byung Jin Kim, Hee Yong Song, Min-Seok Kwon, Byung Gu Min, Sang Min Cho, Jae Sang Jang
  • Patent number: 11027021
    Abstract: This invention relates to treatment of cancer using antibody drug conjugates that comprise PBD molecules in combination with Bcl-2 inhibitors.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: June 8, 2021
    Assignee: Seagen Inc.
    Inventors: William Arthur, Robert Thurman, Travis Biechele, Rory Rohm
  • Patent number: 11013748
    Abstract: Phase-inverted capsules of a prodrug of budesonide are provided for treatment of bowel diseases.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 25, 2021
    Assignee: UNIVERSITY OF NIZWA
    Inventors: Anil K. Philip, Betty Annie Samuel, Hamna Naseer Al Senani, Afaf Mohammed Weli, Ahmed-Sulaiman Fadhil Al Harrasi, Ahmed bin Khalfan Al Rawahi
  • Patent number: 11007179
    Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: May 18, 2021
    Assignee: Allergan Holdings Unlimited Company
    Inventors: Tim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
  • Patent number: 11001585
    Abstract: The present invention relates to crystalline forms of ibrutinib, designated as Form S1, Form S2, Form S3, Form S4, and an amorphous form, designated as Form A1, and processes for their preparation, pharmaceutical compositions comprising these forms, and their use for the treatment of Bruton's tyrosine kinase (BTK) mediated diseases.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: May 11, 2021
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Ramkinkar Santra, Bala Krishna Reddy Bhogala, Chandra Has Khanduri
  • Patent number: 10993933
    Abstract: In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 4, 2021
    Assignee: Astellas Deutschland GmbH
    Inventors: Jeffrey Colledge, Margaretha Olthoff
  • Patent number: 10973769
    Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and a method of using the controlled release oral solid formulation to treat Parkinson's disease or primary parkinsonism.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: April 13, 2021
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 10940127
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 9, 2021
    Assignees: Io Therapeutics, Inc., The Johns Hopkins University
    Inventors: Gabriel Ghiaur, Richard J. Jones, Alonso Salvador, Roshantha A. Chandraratna
  • Patent number: 10933020
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof, and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: March 2, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Patent number: 10925832
    Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: February 23, 2021
    Assignee: Karuna Therapeutics, Inc.
    Inventors: Aimesther Betancourt, Bruce Rehlaender, Roch Thibert
  • Patent number: 10918685
    Abstract: A topical liniment composition that boost muscle relaxation, increase blood flow, and increase cutaneous delivery of herbal extract that contains polyphenols derived from red chili, black pepper, cinnamon, and turmeric includes a quantity of castor-mineral oil-camphor solution, a quantity of eucalyptus oil, a quantity of clove oil, a quantity of peppermint oil, a quantity of frankincense oil, a quantity of herbal extract concentrate solution, and a quantity of castor oil. Aforementioned ingredients are heterogeneously mixed with each other to formulate the topical liniment composition at standard temperature and pressure (STP). Additionally, a quantity of petroleum jelly and a quantity of beeswax can be heterogeneously mixed with the topical liniment composition to formulate the topical balm composition.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: February 16, 2021
    Inventor: Ravi Ramamoorthy Iyer
  • Patent number: 10898438
    Abstract: A package for delivering a single-dose product includes a softgel capsule which is comprised of at least one gelling agent selected from protein-based gelling agents and polysaccharide-based gelling agents. The capsule shell includes one or more areas of reduced thickness that are preferentially ruptured by exertion of a compressive force on the softgel capsule to create an opening in the capsule shell through which the fill composition can be delivered by spraying or squeezing. A method for manufacturing the softgel capsule having one or more areas of reduced shell thickness is also described.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: January 26, 2021
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Laura Baruzzi, David Griffith Williams, Sr., Arianna Provenza, Rodrigo Fuscelli Pytel
  • Patent number: 10899849
    Abstract: A method for the production of empty pullulan capsules eliminate the need to dry pullulan solid product, thereby reducing the equipment cost and energy consumption. The pullulan raw material production can be linked directly with the capsule production to provide a unique approach for empty capsule formation. The purified pullulan fermentation fluid can be directly used in capsule preparation, thus removing the need for a melting process. On the one hand, the method may decrease material consumption, save the cost of equipment and labor, reduce production time and increase productivity. On the other hand, the method may reduce the fluctuating of raw material quality in the re-melting process and guarantee a more stable capsule production and quality.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: January 26, 2021
    Assignee: LEFAN CAPSULE INTERNATIONAL INC
    Inventors: Xianyu Yun, Sheng Wang, Zhongming Fang, Fei Wang, Peiyong Liu, Xiaosan Cao, Zhidong Lu
  • Patent number: 10865160
    Abstract: The present disclosure relates to a nutrient-containing porous biodegradable bead comprising the following components: an Aloe Vera and cellulose composite matrix containing a nutrient solution including, but not limited to, nitrogen, phosphorus, potassium, sodium alginate, and calcium chloride.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: December 15, 2020
    Inventors: Axel Garcia-Burgos, Yoliem S. Miranda-Alanon
  • Patent number: 10813887
    Abstract: The present disclosure provides an acid resistant capsule shell composition including pectin with a degree of esterification (DE) of about 15% to about 40%, and a degree of amidation (DA) of greater than 0% to about 25%; and a divalent cation. An acid resistant capsule shell and a method for manufacturing the acid resistant capsule shell are also provided in the present disclosure.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 27, 2020
    Assignee: DAH FENG CAPSULE INDUSTRY CO., LTD
    Inventors: Ruei-Jan Chang, Yi-Huei Lin, Pei-Hsuan Lee, Hsin-Yi Chao
  • Patent number: 10752589
    Abstract: The present invention provides novel compounds with improved solubility and altered pharmacokinetic properties. The compounds of the present invention may be represented by Formula (I).
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: August 25, 2020
    Assignee: SPHAERA PHARMA PVT. LTD.
    Inventors: Sundeep Dugar, Dinesh Mahajan, Somdutta Sen
  • Patent number: 10736872
    Abstract: A pharmaceutical composition in a physiological dose for a mammal is used for reducing vascular calcification caused due to statin consumption. The composition contains mixture 1 and statin. The mixture 1 contains combination of the Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folic acid, Biotin, L-carnitine and Betaine. The mixture 1 can be used as a stand-alone product with or without statin.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: August 11, 2020
    Inventor: Matthias W Rath
  • Patent number: 10709668
    Abstract: The present invention provides an orally-administrable, pharmaceutical formulation comprising: a plurality of pellets, wherein: the pellets comprise a core, a sustained release coating, and an enteric coating; and the core comprises an active ingredient and a diluent.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: July 14, 2020
    Assignee: CONFLUENCE PHARMACEUTICALS, LLC
    Inventors: Steven L. Johns, Kenneth G. Payie, Badrinath R. Doniparthi, Shivaraj B. Munianjanappa
  • Patent number: 10695367
    Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: June 30, 2020
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd
    Inventors: Ludwig Daniel Weibel, Erik Philipp
  • Patent number: 10695305
    Abstract: The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 30, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & CO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ulrich Matthes
  • Patent number: 10688058
    Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 23, 2020
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 10682322
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: June 16, 2020
    Assignee: FLEXOPHARM BRAIN GMBH & GO. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ralf Linker
  • Patent number: 10682376
    Abstract: Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: June 16, 2020
    Assignee: Vifor Fresenius Medical Care Renal Pharma Ltd
    Inventors: Ludwig Daniel Weibel, Erik Philipp
  • Patent number: 10610543
    Abstract: The invention relates to small cholestyramine pellets that can be prepared by extrusion. The pellets have a high cholestyramine loading and are stable enough to be coated with one or more coating layers. The invention also relates to a process for the preparation of such pellets and to a multiparticulate drug delivery system comprising such pellets.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: April 7, 2020
    Assignee: Albireo AB
    Inventors: Per-Göran Gillberg, Nils Ove Gustafsson, Nils-Olof Lindberg, Jessica Elversson
  • Patent number: 10603286
    Abstract: An aqueous composition for making dip-molded comestible hard capsules comprising a film forming capsule base material and one or more colorants each consisting of a hydrophilic coloring foodstuff concentrate.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: March 31, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Hugues Straub, Stefaan Jaak Vanquickenborne
  • Patent number: 10596122
    Abstract: Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular Crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: March 24, 2020
    Assignee: Medical Research Council
    Inventors: Jonathan Joseph Powell, Nuno Jorge Rodriguez Faria, Laetitia Pele, Rachel Hewitt, Emma Thomas-McKay
  • Patent number: 10588864
    Abstract: Disclosed are pharmaceutical particulates which release a pharmaceutical compound into the colon following oral administration. A particulate comprises a core comprising a pharmaceutical compound, an inner coating surrounding the core, wherein the inner coating comprises a pharmaceutically acceptable polysaccharide that is susceptible to enzymatic digestion by one or more enzymes present colonic microflora, and an outer coating surrounding the inner coating, wherein the outer coating comprises a polymer which is stable at upper gastrointestinal pH but can dissolve at pH>6. The core of a particulate can further comprise an excipient such as a diluent, a binder, a disintegrant, a lubricant, a glidant or a combination thereof. Particulates can comprise pharmaceutical compounds for treating colonic diseases such as C. difficile infection, ulcerative colitis, colon cancer, and Crohn's disease.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: March 17, 2020
    Assignee: Gateway Pharmaceuticals LLC
    Inventor: Lianli Li
  • Patent number: 10555940
    Abstract: Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: February 11, 2020
    Inventor: Robert I. Henkin
  • Patent number: 10525011
    Abstract: A dosage form article consisting of a hard capsule coated with a surface modifying coating wherein the coating is an aqueous composition comprising water and a muco-adhesive polymer selected from the group consisting of poly(acrylates), cellulose derivatives, hyaluronic acid, starch, poly(ethylene glycol), polysaccharides, collagen derivatives, and mixtures thereof, wherein the ratio of the muco-adhesive polymer to water is less than 0.15 by weight of the coating composition.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: January 7, 2020
    Assignee: Capsugel Belgium NV
    Inventors: Dominique Nicolas Cade, Hugues Straub
  • Patent number: 10493032
    Abstract: The invention relates to a nutritional and medicinal oral composition for veterinary use, including a core of complete feed extrudate coated with at least one layer of fat. The layer of fat includes at least one medicinal agent which includes: (i) at least one preconditioned active principle in the form of a solution or a suspension of said active principle in an oily liquid, or (ii) at least one preconditioned active principle in the form of waxy granules.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: December 3, 2019
    Assignee: VIRBAC
    Inventors: Nicolas Brunel, Fanny Martins, Patricia Goisnard
  • Patent number: 10471148
    Abstract: This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: November 12, 2019
    Assignee: TherapeuticsMD, Inc.
    Inventors: Janice Cacace, Peter H. R. Persicaner, Thorsteinn Thorsteinsson, Frederick Sancilio, Julia Amadio, Brian Bernick
  • Patent number: 10420729
    Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquilizers, stimulants and narcotics.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: September 24, 2019
    Assignee: R.P. Scherer Technologies, LLC
    Inventor: Simone Wengner
  • Patent number: 10172803
    Abstract: A problem of the present disclosure is, in one embodiment, to create a hard capsule formulation that includes a pharmaceutical agent or the like whose components deteriorate upon contact with an acid, in which the pharmaceutical agent or the like does not deteriorate due to gastric acid penetrating into the outer shell of the hard capsule. A hard capsule formulation comprising a hard capsule with acid resistance, in which the hard capsule is not treated with enteric coating, and the hard capsule formulation comprises an agent to inhibit invasion of gastric fluid and a pharmaceutical agent in the hard capsule.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: January 8, 2019
    Assignee: Capsugel Belgium NV
    Inventor: Takahisa Takubo
  • Patent number: 10155041
    Abstract: The present invention relates to the field of gastroenterology and, more particular, to the field of intestinal diseases. More specifically, it concerns uses and methods for the treatment of inflammatory bacterial diseases of the intestine. In particular, it relates to diseases that are associated with bacterial invasion of the intestinal mucus, including, inflammatory bowel diseases, and infectious bacterial diseases. Therefore, the present invention provides agents, a pharmaceutical composition and a kit for treating said diseases. It further relates to a use and a method for treating invasive bacterial diseases of the large intestine.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 18, 2018
    Assignee: Universitaetsklinikum Heidelberg
    Inventor: Wolfgang Stremmel
  • Patent number: 10149895
    Abstract: Described herein is an association of at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive antihypertensive agent and at least one antifibrotic agent for the management of progressive renal diseases including chronic kidney diseases (CKD) in domestic carnivores. Specifically, the application describes veterinarian compositions comprising such an association and the use thereof for the treatment of CKD conditions.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 11, 2018
    Assignee: VIRBAC
    Inventors: Natalia Bernachon, Patricia Monginoux
  • Patent number: 10004691
    Abstract: Provided is an orally disintegrating tablet which shows high stability of the active ingredients (acetylsalicylic acid and PPI), and expresses the pharmacological effects of the active ingredients stably and rapidly after administration. A multiple-unit type orally disintegrating tablet containing enteric-coated micro granules containing acetylsalicylic acid, enteric-coated micro granules containing a proton pump inhibitor, and an additive, wherein an enteric coating layer of the enteric-coated micro granules containing acetylsalicylic acid contains an aqueous enteric polymer base and a sustained-release base.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: June 26, 2018
    Assignee: Takeda Pharmaceuticals Company Limited
    Inventors: Tetsuya Kawano, Yumiko Ishii
  • Patent number: 9937231
    Abstract: The present disclosure provides compositions and methods useful for treating or preventing diseases or disorders where beta amyloid accumulation or aggregation contributes to the pathology or symptomology of the disease, for example Alzheimer's disease.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: April 10, 2018
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Rudolph Emile Tanzi, Ana Griciuc
  • Patent number: 9925148
    Abstract: The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with bulk enteric properties. The present disclosure also relates, in part, to aqueous dispersions suitable for the implementation of said manufacturing process, and to enteric capsule shells and hard capsules obtained therewith.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: March 27, 2018
    Assignee: Capsugel Belgium NV
    Inventors: Hassan Benameur, Dominique Nicolas Cade, Sophie Schreiber
  • Patent number: 9901588
    Abstract: Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 27, 2018
    Assignee: Nestlé Skin Health SA
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Rajeev Singh Raghuvanshi
  • Patent number: 9867865
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using mesalamine are disclosed herein. Mesalamine can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 16, 2018
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 9839632
    Abstract: Methods and compositions for treating, preventing or managing central nervous system cancers are disclosed. The methods encompass the administration of 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione, also known as Pomalidomide. Furthermore, provided herein are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: December 12, 2017
    Assignee: Celgene Corporation
    Inventor: Han W. Tun
  • Patent number: 9814683
    Abstract: A shell-forming composition for a soft capsule comprising a non-gelatin component as the chief component, wherein the shell-forming composition is able to inhibit a decrease in physical strength (breaking strength) of the capsule when a phospholipid-containing oil with a phospholipid concentration of 20% or more by mass is used as the core of the capsule. The shell-forming composition for the soft capsule comprises (A) starch and/or dextrin, (B) a gelatinizer, (C) glycerin and (D) sorbitol, and the mass ratio of (C) glycerin:(D) sorbitol ranges from 100:30 to 100:120.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: November 14, 2017
    Assignee: R.P. SCHERER TECHNOLOGIES, LLC
    Inventors: Takuma Fujii, Toshikazu Okayama, Michihiro Kimata, Yoshiaki Hanayama, Miyako Takahashi
  • Patent number: 9795569
    Abstract: A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 24, 2017
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Brendan Muldoon, Ryan Gerald Loughlin, Gerarde Sweeney, Emma Karen Boyd
  • Patent number: 9789187
    Abstract: The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from ?-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: October 17, 2017
    Assignee: Cadila Pharmaceuticals Limited
    Inventors: Bakulesh Mafatlal Khamar, Kumud Kumar Padhee, Nilamkumari Somalal Patel, Sunil Chowdary Koduri, Amit Mukharya, Indravadan Ambalal Modi, Rajiv Indravadan Modi